Publications by authors named "Cory Gamble"

Claim this Profile
M
Macrovascular and microvascular complications in US Medicare enrollees with type 2 diabetes with and without atherosclerotic cardiovascular disease.
Tyler J Dunn, Xi Tan, Joanna Harton, Sonia Kim, Lin Xie, Cory Gamble

Diabetes Obes Metab· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE).
James Amamoo, Riddhi Doshi, Joshua Noone, Lin Xie, Cory Gamble

Diabetes Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: A retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease.
Tyler J Dunn, Yong Zhu, Noelle N Gronroos, Lin Xie, Andrew Sargent, Cory Gamble

Diabetes Res Clin Pract· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world HbA changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes.
Monica Frazer, Caroline Swift, Andrew Sargent, Michael Leszko, Erin Buysman, Cory L Gamble

J Diabetes Metab Disord· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Xi Tan, Victoria Divino, James Amamoo, Lin Xie, Katharine B Coyle, Cory L Gamble

Clin Drug Investig· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.
Xi Tan, Yuanjie Liang, Cory Gamble, Aaron King

Diabetes Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry.
Suzanne V Arnold, Kensey Gosch, Mikhail Kosiborod, Nathan D Wong, Laurence S Sperling, Cory L Gamble

Am Heart J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database.
Chioma Uzoigwe, Josh Noone, Yuanjie Liang, Sarah Naz Ali, Cory Gamble

Diabetes Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucose-lowering treatment patterns in patients with diabetic kidney disease.
Neeraj N Iyer, Qian Li, Surbhi Shah, Michael L Ganz, Tam Dang-Tan, Cory Gamble

Am J Manag Care· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring Why People With Type 2 Diabetes Do or Do Not Persist With Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Qualitative Study.
William Polonsky, Cory Gamble, Neeraj Iyer, Mona Martin, Carol Hamersky

Diabetes Spectr· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Effectiveness of Liraglutide vs. Sitagliptin Among Older Patients with Type 2 Diabetes Enrolled in a Medicare Advantage Prescription Drug Plan: A Retrospective Observational Study.
Tam Dang-Tan, Pravin S Kamble, Yunus Meah, Cory Gamble, Rahul Ganguly

Diabetes Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes.
Carol M Hamersky, Moshe Fridman, Cory L Gamble, Neeraj N Iyer

Diabetes Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.
Dhvani Shah, Nancy A Risebrough, Johnna Perdrizet, Neeraj N Iyer, Cory Gamble

Clinicoecon Outcomes Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.
Qian Li, Rahul Ganguly, Michael L Ganz, Cory Gamble, Tam Dang-Tan

Diabetes Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CLCN2 chloride channel mutations in familial hyperaldosteronism type II.
Ute I Scholl, Gabriel Stölting, Julia Schewe, Anne Thiel, Hua Tan, Cory Gamble

Nat Genet· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis